The effect of low-dose esketamine for patient-controlled analgesia after thoracoscopic surgery on acute and chronic pain

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100045298

Enrollment

Unknown

Registered

2021-04-10

Start date

2021-04-15

Completion date

Unknown

Last updated

2021-11-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative pain

Interventions

S group:Esketamine combined with sufentanil for PCA

C group:Sufentanil for PCA

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.Aged between 18 and 70 years old; 2.BMI between 18 and 30; 3.The ASA score II or III; 4.Clearly understand and voluntarily participate in the study, and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1.Allergic to experimental drugs, chronic pain, drug or alcohol abuse; 2.Emergency surgery; 3.Mental disorders; 4.Abnormal liver and kidney function.

Design outcomes

Primary

Measure	Time frame
Numerical Pain Score;	—

Secondary

Measure	Time frame
Consumption of Sufentanil;Analgesia pump compressions;Incidence of adverse reaction;Incidence of chronic pain;	—

Countries

China

Contacts

Public ContactChen Ying

The First People's Hospital of Lianyungang

chy366@163.com+86 18961322003

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026